DepressionPhase 2NCT01069952
Electrical Stimulation of the Internal Capsule for Intractable Depression
A Phase 2 study testing Deep Brain Stimulation System in people with Depression, run by Butler Hospital at 1 site in United States.
Trial summary
This study will evaluate the safety and efficacy of deep brain stimulation in treating people with several and otherwise treatment-resistant depression. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Depression
- What is being tested?
- Deep Brain Stimulation System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2002to May 2004
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Major depression, severe, unipolar type, diagnosed by Structural Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity.
- 24-item Hamilton Depression Rating Scale (HDRS) of at least 21.
- Global Assessment of Function (GAF) score of 45 or less.
- A recurrent (greater than or equal to 4 episodes) or chronic (episode duration greater than or equal to two years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior).
- Failure to respond to respond to:
- Adequate trials (greater than or equal to 6 weeks at the maximum recommended or tolerated dose) of primary antidepressants from at least 3 different classes and;
Show all 13Show fewer
- Adequate trials (greater than or equal to 4 weeks at the usually recommended or maximum tolerated dose of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant) and;
- An adequate trial of individual psychotherapy (greater than or equal to 20 sessions with an experienced psychotherapist)
- Age 18 to 65 years
- Able to comply with the operational and administrative requirements of participation in the study.
- Able to give written informed consent.
- Either drug-free or on a stable drug regimen for at least 6 weeks at the time of entry into the study.
- Good general health.
Who cannot join
- Current or past non-affective psychotic disorder.
- Any current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome.
- Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
- Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo pre-surgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery.
- Current or unstably remitted substance abuse.
- Pregnancy and women of childbearing age not using effective contraception.
Show all 9Show fewer
- History of severe personality disorder.
- Imminent risk of suicide (based on the judgment of the investigators).
- Not able to comply with the operational and administrative requirements of participation in the study (based on the judgment of the investigators).
Trial locations and contacts
1 site in 1 country.
About this study
This study will evaluate the safety and efficacy of deep brain stimulation in treating people with several and otherwise treatment-resistant depression.
Read the detailed description
Despite the availability of effective treatments, a substantial portion of patients fail to recover from episodes of depression. Assuming a conservative rate of 20%, and given the prevalence of major depression in the general population, over 3.5 million Americans would be expected to manifest refractory illness if all those with depression received treatment. Although rarely used in the U.S., neurosurgical approaches to severely refractory depression have shown efficacy in a number of uncontrolled studies, primarily from European investigators. Deep brain stimulation (DBS) is a procedure that involves the use of thin wires to carry electric current to parts of the brain associated with producing depression symptoms. DBS has been effectively and safely used to treat movement disorders, such as Parkinson's disease, and may be beneficial in reducing depression symptom severity. This study will evaluate the safety and efficacy of DBS in treating people with severe and treatment-resistant depression.
Study participation through follow-up will last up to three years. Participants will be allowed to remain on any pre-surgical medications or behavioral therapy programs throughout the study. Before surgery, all participants will undergo a series of initial tests and examinations that will include a physical and neurological examination; laboratory testing to screen for significant hematologic, hepatic, renal or endocrine abnormalities; and detailed psychological testing including tests of perception, learning, and memory.
Implantation of all devices will be preformed at a single session. The patient will undergo local anesthesia for the implantation of the leads, and the implanted pulse generator will be implanted under general anesthesia. On the day of the surgery, participants will have a metal frame fixed to their heads for support during surgery. Using coordinates individually determined by preoperative MRI, a pair of tetrapolar leads will be inserted into the anterior limb of each internal capsule and fixed to the skull with a burr hole ring and cap. The leads will be inserted so that the stimulation sites span the dorsal-ventral extent of the anterior capsule or target the ventral half of the anterior capsule.
After placement of the DBS system, the patient will be admitted to the hospital for overnight evaluation for possible complications of the procedure, including possible hemorrhage or infection. Postoperative evaluation will consist of physical and neurological examinations, postoperative CBC, electrolyte panel, plain x-ray studies of head, neck, and chest including a standard shunt series to ensure integrity of connections and to document positioning of stimulating hardware. A head CT scan will be obtained within 24 hours postoperatively to monitor for possible postoperative intracranial hemorrhage.
If none of the above complications occur, the patient will be discharged home the following day with the DBS system off to allow resolution of the cellular reactions to electrode placement. Three weeks after placement of the DBS system, the patient will return to being the outpatient phase of testing the effects of stimulation.
During the intensive outpatient phase of the study, each of the outpatient visits will last approximately two hours. These are anticipated to occur at from 1 to 5 day intervals. On each day, we will do a brief clinical interview and obtain structured ratings of depressive symptoms, mood and affect, possible side effects, and cognition.
After completion of the two year study, patients will be given the choice of continued DBS, for a total of three years after implantation, or until the stimulator batteries fail. Patients will also be offered alternative treatment, outside of this study, including anterior capsulotomy, depending on availability given the patient's financial circumstances and insurance coverage, or further conventional therapy. Long-term patient follow-up will continue indefinitely where possible.
During this study, patients will also be invited to undergo a series of three Positron Emission Tomography (PET) scans under a separate IRB protocol at Massachusetts General Hospital, to assess the effects of capsular stimulation on activity in brain circuits implicated in depression. Subjects' participation in this separate protocol is not a condition for entering the DBS study.
- Conditions
- Depression
- Being tested
- Deep Brain Stimulation System
- Keywords
- Deep Brain Stimulation, Treatment Refractory, Neurosurgery, Implantable Neurostimulator (INS), Internal Capsule
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Deep Brain Stimulation SystemDevice
Also called Deep Brain Stimulation System from Medtronic, Inc., Implantable Neurostimulator (INS)
In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
| Study group | Role | What they receive |
|---|---|---|
| Active DBS | Experimental | Participants will receive deep brain stimulation. Receives: Device: Deep Brain Stimulation System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hamilton Depression Rating Scale (HDRS)
Measured: Administered at base line, every 1 to 5 days during the acute phase (2 months), monthly during the chronic phase, then every three months during the open continuation phase
Secondary outcomes (1)
Inventory for Depressive Symptoms, Self Report (IDS-SR)
Measured: Administered at base line, every 1 to 5 days during the acute phase (2 months), monthly during the chronic phase, then every three months during the open continuation phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2010 (estimated)
- Study startDec 2002
- Primary completionMay 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Butler Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Medtronic
- Responsible party
- Principal investigator, Dr. Benjamin Greenberg, Butler Hospital
- Investigators
- Benjamin D Greenberg, MD, PhD, Principal investigator, Butler Hospital/Brown University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01069952
- Sponsor's protocol ID
- G010351
- Other IDs
- 0201-001
- Status last verified
- Jul 2012
- First submitted
- 16 Feb 2010
- Last updated
- 24 Jul 2012
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009 Feb 15;65(4):267-75. doi: 10.1016/j.biopsych.2008.08.029. Epub 2008 Oct 8.
PubMed 18842257Carpenter LL, Friehs GM, Tyrka AR, Rasmussen S, Price LH, Greenberg BD. Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. Med Health R I. 2006 Apr;89(4):137, 140-1.
PubMed 16676910
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Electrical Stimulation of the Internal Capsule for Intractable Depression
- ClinicalTrials.gov ID
- NCT01069952
- Acronym / sponsor ID
- G010351
- Conditions
- Depression
- Keywords
- Deep Brain Stimulation, Treatment Refractory, Neurosurgery, Implantable Neurostimulator (INS), Internal Capsule
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Butler HospitalUniversity, hospital or other
- Collaborators
- Medtronic
- Study start
- Dec 2002
- Primary completion
- May 2004 (actual)
- First posted
- 17 Feb 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the safety and efficacy of deep brain stimulation in treating people with several and otherwise treatment-resistant depression.
Detailed description
Despite the availability of effective treatments, a substantial portion of patients fail to recover from episodes of depression. Assuming a conservative rate of 20%, and given the prevalence of major depression in the general population, over 3.5 million Americans would be expected to manifest refractory illness if all those with depression received treatment. Although rarely used in the U.S., neurosurgical approaches to severely refractory depression have shown efficacy in a number of uncontrolled studies, primarily from European investigators. Deep brain stimulation (DBS) is a procedure that involves the use of thin wires to carry electric current to parts of the brain associated with producing depression symptoms. DBS has been effectively and safely used to treat movement disorders, such as Parkinson's disease, and may be beneficial in reducing depression symptom severity. This study will evaluate the safety and efficacy of DBS in treating people with severe and treatment-resistant depression.
Study participation through follow-up will last up to three years. Participants will be allowed to remain on any pre-surgical medications or behavioral therapy programs throughout the study. Before surgery, all participants will undergo a series of initial tests and examinations that will include a physical and neurological examination; laboratory testing to screen for significant hematologic, hepatic, renal or endocrine abnormalities; and detailed psychological testing including tests of perception, learning, and memory.
Implantation of all devices will be preformed at a single session. The patient will undergo local anesthesia for the implantation of the leads, and the implanted pulse generator will be implanted under general anesthesia. On the day of the surgery, participants will have a metal frame fixed to their heads for support during surgery. Using coordinates individually determined by preoperative MRI, a pair of tetrapolar leads will be inserted into the anterior limb of each internal capsule and fixed to the skull with a burr hole ring and cap. The leads will be inserted so that the stimulation sites span the dorsal-ventral extent of the anterior capsule or target the ventral half of the anterior capsule.
After placement of the DBS system, the patient will be admitted to the hospital for overnight evaluation for possible complications of the procedure, including possible hemorrhage or infection. Postoperative evaluation will consist of physical and neurological examinations, postoperative CBC, electrolyte panel, plain x-ray studies of head, neck, and chest including a standard shunt series to ensure integrity of connections and to document positioning of stimulating hardware. A head CT scan will be obtained within 24 hours postoperatively to monitor for possible postoperative intracranial hemorrhage.
If none of the above complications occur, the patient will be discharged home the following day with the DBS system off to allow resolution of the cellular reactions to electrode placement. Three weeks after placement of the DBS system, the patient will return to being the outpatient phase of testing the effects of stimulation.
During the intensive outpatient phase of the study, each of the outpatient visits will last approximately two hours. These are anticipated to occur at from 1 to 5 day intervals. On each day, we will do a brief clinical interview and obtain structured ratings of depressive symptoms, mood and affect, possible side effects, and cognition.
After completion of the two year study, patients will be given the choice of continued DBS, for a total of three years after implantation, or until the stimulator batteries fail. Patients will also be offered alternative treatment, outside of this study, including anterior capsulotomy, depending on availability given the patient's financial circumstances and insurance coverage, or further conventional therapy. Long-term patient follow-up will continue indefinitely where possible.
During this study, patients will also be invited to undergo a series of three Positron Emission Tomography (PET) scans under a separate IRB protocol at Massachusetts General Hospital, to assess the effects of capsular stimulation on activity in brain circuits implicated in depression. Subjects' participation in this separate protocol is not a condition for entering the DBS study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Active DBS | Experimental | Device: Deep Brain Stimulation SystemParticipants will receive deep brain stimulation. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Major depression, severe, unipolar type, diagnosed by Structural Clinical Interview for DSM-IV (SCID-IV), judged to be of disabling severity.
- 24-item Hamilton Depression Rating Scale (HDRS) of at least 21.
- Global Assessment of Function (GAF) score of 45 or less.
- A recurrent (greater than or equal to 4 episodes) or chronic (episode duration greater than or equal to two years) course and a minimum of 5 years since the onset of the first depressive episode. Major impairment in functioning or potentially severe medical outcomes (repeated hospitalizations, serious suicidal or other self-injurious behavior).
- Failure to respond to respond to:
Key exclusion criteria (9 listed)
- Current or past non-affective psychotic disorder.
- Any current clinically significant neurological disorder or medical illness affecting brain function, other than motor tics or Gilles de la Tourette syndrome.
- Any clinically significant abnormality on preoperative magnetic resonance imaging (MRI).
- Any surgical contraindications to undergoing DBS, including labeled contraindications for DBS and/or inability to undergo pre-surgical MRI (cardiac pacemaker, pregnancy, metal in body, severe claustrophobia), infection coagulopathy, inability to undergo an awake operation, significant cardiac or other medical risk factors for surgery.
- Current or unstably remitted substance abuse.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Deep Brain Stimulation SystemAlso: Deep Brain Stimulation System from Medtronic, Inc., Implantable Neurostimulator (INS)In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. | Device | Active DBS |
Primary outcome
Hamilton Depression Rating Scale (HDRS)
Time frame: Administered at base line, every 1 to 5 days during the acute phase (2 months), monthly during the chronic phase, then every three months during the open continuation phase
1 secondary outcome
Inventory for Depressive Symptoms, Self Report (IDS-SR)
Time frame: Administered at base line, every 1 to 5 days during the acute phase (2 months), monthly during the chronic phase, then every three months during the open continuation phase
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2012.
- Results publication: PubMed 18842257Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009 Feb 15;65(4):267-75. doi: 10.1016/j.biopsych.2008.08.029. Epub 2008 Oct 8.
- Results publication: PubMed 16676910Carpenter LL, Friehs GM, Tyrka AR, Rasmussen S, Price LH, Greenberg BD. Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. Med Health R I. 2006 Apr;89(4):137, 140-1.
Related trials for Depression
Not yet recruiting
Mandala Coloring in Late Pregnancy
Pregnancy, Anxiety
Not yet recruitingObservational study
Ecological Momentary Assessment of State-Dependent Decision-Making and Metacognition Across a Psychopathology Continuum
Depression, Anxiety
Not yet recruiting
Adapting the ESTEEM Intervention to Improve Mental Health and PrEP Uptake Among Men at Risk of HIV
PrEP Use
Recruiting
Cancer Pain Management Using a Web-based Intervention
Cancer of Breast, Depressive Symptoms
Active, not recruiting
Improving Student Mental Health Through a Universal Trauma-Informed Intervention
Anxiety Symptoms, Post-traumatic Stress Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin D Greenberg, MD, PhD principal investigator
Butler Hospital/Brown University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Deep Brain Stimulation System in people with Depression, run by Butler Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hamilton Depression Rating Scale (HDRS) (time frame: Administered at base line, every 1 to 5 days during the acute phase (2 months), monthly during the chronic phase, then every three months during the open continuation phase). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01069952, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2012.